Prexigebersen-A is under clinical development by Bio-Path and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Prexigebersen-A’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Prexigebersen-A is under development for the treatment of solid tumors including ovarian cancer, peritoneal cancer, fallopian tube cancer, uterine cancer, triple-negative breast cancer and inflammatory breast cancer, endometrial cancer, prostate cancer and metastatic pancreatic cancer. Prexigebersen-A is a slightly modified formulation of prexigebersen designed to enhance nanoparticle properties. It is administered by intravenous route. The therapeutic candidate targets Grb-2 (growth factor-bound protein-2). It is developed based on DNAbilize liposomal antisense technology.
Bio-Path is a clinical stage biotechnology company that develops targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company provides products pipeline such as prexigebersen and BP1002 (Liposomal Bcl2). Its prexigebersen, is developed for the treatment of Acute Myeloid Leukemia (AML) and solid tumors. Bio-Path’s BP1002 (Liposomal Bcl2) is used for the treatment of lymphoma, leukemia, colon, prostate and breast cancers, among others. The company’s proprietary liposomal delivery and antisense technology platform DNAbilize, is used to systemically distribute nucleic acid drugs throughout the human body with a simple intravenous transfusion. Bio-Path is headquartered in Bellaire, Texas, the US.
For a complete picture of Prexigebersen-A’s drug-specific PTSR and LoA scores, buy the report here.